

In the claims:

Please cancel, without prejudice, Claims 2, 10-15, 22, 30-36 and 38.

Please amend Claims 1, 9, 21, 29 and 37 as follows:

Q12
Pkt B2
1. A method of treating an IL-17 mediated, inflammatory cartilagenous disorder comprising contacting the cartilage with an effective amount of anti-IL-17 antibody.

Q13
Pkt B3
9. The method of Claim 8, wherein the antagonist to IL-17 is administered by direct injection into an afflicted cartilagenous region or joint.

Q14
21. A method of reducing further cartilage damage caused by a cartilagenous disorder comprising contacting the cartilage with an effective amount of an anti-IL-17 antibody.

Q15
Pkt B4
29. The method of Claim 28, wherein the IL-17 antagonist is administered by direct injection into an afflicted cartilagenous region or joint.

Q16
Pkt B5
37. A method of treating a mammal suffering from an IL-17 mediated, inflammatory cartilagenous disorder, comprising administering to said mammal a therapeutically effective amount of an anti-IL-17 antibody.

Please add the following new claims:

Q17
45. (New claim). The method of Claim 40, wherein the arthritis is rheumatoid arthritis.

46. (New claim). The method of Claim 40, wherein the arthritis is osteoarthritis.

The specification amendments correct for various clerical errors.

Support for the amendments and new claims appears at least as follows:

Claim 1, Claim 37: “IL-17 mediated, inflammatory cartilagenous disorders”. Example 16, page 88, line 30 through page 91, line 5.

Claims 45, 46: Page 6, lines 36-37, figures 12-13, age 12, lines 13-31, page 20, lines 27-30.